N/A N=30 Pain Modulatory Profiles in Stretching
Healthy
Primary: Change in Pressure Pain Threshold — 317.27; 286.73; 304.69 kilopascals
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Extended Depth of Focus Contact Lenses for Presbyopia
Presbyopia
Primary: LogMAR Visual Acuity — -0.07 logMAR
Phase 2 N=20 Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19
Covid19
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) Within the CX-4945 Treatment Group — 9; 4 Participants
N/A N=199 Perceptions of Cigarette Smoking in Young Adults
Smoking, Cigarette
Primary: Subjective Response to Smoking Cigarettes From the Cigarette Evaluation Scale — 4.68; 4.50 score on a scale — p=>.05
N/A N=27 Feasibility of the Camp Power Up Program on Children's Body Weight and Quality of Life
Obesity, Childhood · Weight Change, Body · Quality of Life
Primary: Change in Body Weight — .3 kg
N/A N=186 Organizational Skills Training - Tier 2 (OST-T2)
Executive Function · Behavioral Research · Schools
Primary: Students' Organizational Functioning - Teacher Report — 2.89; 2.86; 2.27; 2.71 scores on a scale — p=<.001
Phase 3 N=25 A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
Symptomatic Transthyretin Amyloid Cardiomyopathy
Primary: Part A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT) — -3.86 meters
N/A N=83 Intensive Unimanual (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegia
Cerebral Palsy · Hemiplegia · Children
Primary: Jebsen-Taylor Test of Hand Function — 323.6; 479.5; 265.6; 121.3 seconds
N/A N=83 Continuum™ Metal Bearing System in Total Hip Arthroplasty
Avascular Necrosis · Osteoarthritis · Inflammatory Arthritis
Primary: Implant Survival at 10 Years — 98.8; 97.5; 96.16; 96.16 percentage of participants
Phase 2 N=77 Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
Ovarian Cancer
Primary: Occurrence of Palmar-plantar Erythrodysesthesia (PPE) — 18; 9; 3; 0 Participants
Phase 1 N=24 Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution)
Healthy
Primary: Cmax of Tramadol Hydrochloride for the Test and the Reference Products — 139.65; 123.90 ng/mL
N/A N=69 The Body Project: Comparing the Effectiveness of an In-person and Virtually Delivered Intervention.
Eating Disorders
Primary: Change Over Time in Body Dissatisfaction — .42; 0.51 score on a scale
N/A N=79 AAT-App Outpatient Trial
Alcohol Use Disorder (AUD)
Primary: Number of Standard Drinks Consumed Per Week — 38.469; 29.645; 33.199; 28.801 standard drinks (10 grams alcohol) — p=.026
Phase 2 N=24 Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
Head and Neck Squamous Cell Carcinoma · Malignant Solid Neoplasm
Primary: Phase I: The Recommended Phase II Dose Determenation. Phase II: Overall Response Rate (ORR) and Progression Free Survival (PFS) — 40 mg
Phase 2 N=175 Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
Hypertension
Primary: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) — 73 Participants